Immunotherapy Archives

Best in Biotech 15 Mar 2023

10 immunotherapy companies making waves in 2023

Immunotherapy has been widely studied in cancer treatment research, ever since William Coley, who is regarded as the father of immunotherapy, first attempted to leverage the immune system for oncological therapy in 1891. Soon enough, the transformative power of cancer vaccines were observed where tumor-specific antigens triggered antitumor immune responses. Along with these technological advancements, […]

March 15, 2023 - 10 minutesmins - By Roohi Mariam Peter

News and Trends 14 Mar 2023

How the microbiome can predict cancer immunotherapy success

A new study shows antibiotic treatment prior to CAR-T cell therapy is connected to unfavorable treatment outcomes. An international team headed by Eran Elinav of the Cancer & Microbiome Division of the German Cancer Research Center (DKFZ), and led by Christoph Stein-Thoeringer, professor of Clinical Infectiology and Translational Microbiome Research at the Medical Faculty of […]

March 14, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 24 Feb 2023

AELIX announces ‘important step towards HIV eradication’

AELIX Therapeutics S.L., a clinical-stage biotechnology company specializing in the discovery and development of immunotherapies for HIV infection, has announced positive topline results from its AELIX-003 trial. The study evaluated the safety, tolerability, immunogenicity and efficacy of AELIX Therapeutics’ HTI T-cell therapeutic HIV vaccine in combination with Gilead’s investigational Toll-Like Receptor 7 (TLR7) agonist, vesatolimod […]

February 24, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 16 Feb 2023

Cytovation melanoma study under way

Cytovation ASA, a Norwegian clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces that the first patient has been dosed in its phase 2a study. The trial is investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to checkpoint inhibitors (CPIs). The study is an expansion arm […]

February 16, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

TILT Biotherapeutics closes €22M financing for oncology immunotherapy trials

TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, has closed its €22 million ($23.8 million) round. This follows on from the first close of €10 million in June 2022. The financing was led by Finland’s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs. The funding will be used to advance […]

February 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Mnemo Therapeutics and Institut Curie studies lead to cancer-specific targets

Mnemo Therapeutics, a French biotechnology company developing immunotherapies, has announced publication of two scientific studies developed at Institut Curie, its closest academic collaborator, in the journal Science Immunology. The publications reveal TE-exon splicing junctions act as a source of novel recurrent, cancer-specific targets and have potential implications for developing more effective and less toxic immunotherapies. […]

February 7, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 1 Feb 2023

Next-generation small molecules hold promise for immunotherapy

By Ian B. Walters, chief executive officer and chairman, Portage Biotech In recent years, PD-1/PD-L1 checkpoint antibody therapies have revolutionized the immuno-oncology landscape and offered cancer patients the hope for a long term treatment and cure of their disease. While these treatments have shown great promise in reversing T-cell exhaustion, many patients still have limited […]

February 1, 2023 - 3 minutesmins - By External Contributor

News and Trends 31 Jan 2023

The next breakthrough in cancer treatment?

In our body, we have an innate immune system and an immune system that is developed throughout life. Part of the innate immune system consists of so-called NK (natural killer) cells. This is a type of immune cell that specializes in killing cancer cells. These cells may be of great importance for cancer treatment in […]

January 31, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

HKUMed uncovers T cell exhaustion factor driving cancer immunotherapy resistance

A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has identified an unexpected driver of cancer immunotherapy resistance: the harmful effect of chronic Type I Interferon signaling on tumor-killing CD8+ T cells. The findings provided new insights into the development of exhausted CD8+ T cells, which no longer effectively […]

January 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 20 Jan 2023

Brenus Pharma and InSphero bag €1.5M for next-generation cancer cell immunotherapy

Brenus Pharma and InSphero AG have received a €1.5 million grant for the collaborative project “STC-1010: A First-in-Class Allogeneic Cell Vaccine Against Cancer,” which aims to use 3D cell culture to develop a novel cell immunotherapy for colorectal cancer. Funding was provided by the Eurostars fund, a support mechanism for small and medium-sized enterprises under […]

January 20, 2023 - 4 minutesmins - By Jim Cornall

In Depth 20 Dec 2022

Ebvallo approval ushers in off-the-shelf T-cell immunotherapies

Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU approval of Atara Biotherapeutics’ Ebvallo marks the first immunotherapy based on T cells sourced from healthy donors. Since the approvals of Kymriah and Yescarta in 2017, CAR-T immunotherapies have changed the way we treat rare forms of blood cancer. In […]

December 20, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 20 Dec 2022

Watch: Valo Therapeutics at Bio-Europe

Valo Therapeutics Oy is a Finnish immunotherapy company developing antigen-coated oncolytic viruses and vaccine vectors as innovative immunotherapy approaches against cancer and infectious disease. The Valo Therapeutics lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed at the laboratory of Vincenzo Cerullo at the University of Helsinki in Finland. It turns oncolytic adenoviruses into targeted […]

December 20, 2022 - 1 minutemin - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

10 immunotherapy companies making waves in 2023

How the microbiome can predict cancer immunotherapy success

AELIX announces ‘important step towards HIV eradication’

Cytovation melanoma study under way

TILT Biotherapeutics closes €22M financing for oncology immunotherapy trials

Mnemo Therapeutics and Institut Curie studies lead to cancer-specific targets

Next-generation small molecules hold promise for immunotherapy

The next breakthrough in cancer treatment?

HKUMed uncovers T cell exhaustion factor driving cancer immunotherapy resistance

Brenus Pharma and InSphero bag €1.5M for next-generation cancer cell immunotherapy

Ebvallo approval ushers in off-the-shelf T-cell immunotherapies

Watch: Valo Therapeutics at Bio-Europe

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!